Jcr Pharmaceuticals (4552 JP): Mainstay Drug Revenue Declining; High R&D Cost Worsens Profitability
Revenue from JCR’s flagship drug Growject declined 7% to ¥9.3B during 9MFY23, due to the negative impact of insurance price. As R&D cost is...
568 Views
Opko Health (OPK US): Diagnostic Business on Solid Grip; Pharmaceutical Business Ready to Take-Off
Opko Health’s pharmaceutical business is set to see couple of product launches in the international markets, while its diagnostic business is on a...
413 Views
Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28
Ziopharm Oncology Inc (ZIOP US) announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric...
2.1k Views
Just In: Trump's Preliminary Plan to Repeal the Affordable Care Act
Among one of his first initiatives, U.S. President-elect Trump posted a preliminary plan to repeal the Affordable Care Act (ACA) on his transition...
560 Views
Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector:Mid-Week Update (October 27)
SummaryWe discuss our portfolio companies Acadia Pharmaceuticals Inc (ACAD US), Portola Pharmaceuticals Inc (PTLA US), Dynavax Technologies Corp...
341 Views